Performance of <scp>mRNA</scp>‐ and <scp>DNA</scp>‐based high‐risk human papillomavirus assays in detection of high‐grade cervical lesions

Virtanen, Elina; Kalliala, Ilkka; Dyba, Tadeusz; Nieminen, Pekka; Auvinen, Eeva

doi:10.1111/aogs.13041

Cited by 11 publications

(15 citation statements)

References 32 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study assessed the follow‐ups of both the Cervista and Aptima tests in women with LSIL cytology and the results demonstrated that both platforms had similar clinical performance in detecting CIN2 + lesions. In the current study, we failed to reproduce the improved specificity in the general population with the Aptima assay, a result that is consistent with recent reports comparing the clinical performance of Aptima and HC2, which also demonstrated similar performance, including specificity …”

Section: Discussionsupporting

confidence: 91%

“…Previous studies have demonstrated that the Aptima HrHPV assay has similar sensitivities but superior specificities for precancerous lesions (CIN2/3) when compared with the HPV DNA testing platforms (mostly the HC2 method), and suggested the HPV messenger RNA (mRNA) test is a better triage test for women with LSIL. However, other evidence demonstrated that there was no significant difference between HPV DNA‐based and RNA‐based assays with regard to clinical performance for the detection of high‐grade cervical lesions . In the current study, we assessed the histopathologic follow‐up of the Aptima HPV RNA and Cervista HPV DNA assays in women with LSIL cytology in a large academic institution to evaluate which was the better strategy for the triage of women with LSIL cytology.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Zhang

Varma

Han

et al. 2018

Cancer Cytopathology

View full text Add to dashboard Cite

The Aptima assay was found to be statistically significantly more specific than the Cervista test for detecting CIN2/3 lesions among women aged ≥50 years. These findings not only further support the recommendations by the American Society for Colposcopy and Cervical Pathology that hrHPV triage is an acceptable option for postmenopausal women with LSIL cytology, but also provide additional evidence that HPV RNA testing may be more useful in clinical risk stratification due to its specificity in the postmenopausal population. Cancer Cytopathol 2018. © 2018 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 95%

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Zhang

Varma

Han

et al. 2018

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

“…Recent studies suggest that HPV mRNA testing has improved specificity for grade 2 cervical intraepithelial neoplasia (CIN2) or worse (≥CIN2) compared with HPV DNA assays . However, other studies concluded that there was no significant difference between HPV DNA and RNA testing methods in clinical performance for the detection of high‐grade cervical lesions . The purpose of the current study was to analyze the performance of the 2 most common HPV testing platforms (Cobas and Aptima) in detecting high‐grade cervical lesions that were confirmed by biopsy.…”

Section: Introductionsupporting

confidence: 91%

“…[12][13][14] However, other studies concluded that there was no significant difference between HPV DNA and RNA testing methods in clinical performance for the detection of high-grade cervical lesions. 15,16 The purpose of the current study was to analyze the performance of the 2 most common HPV testing platforms (Cobas and Aptima) in detecting high-grade cervical lesions that were confirmed by biopsy.…”

Section: Introductionmentioning

confidence: 99%

Performance of Aptima and Cobas HPV testing platforms in detecting high‐grade cervical dysplasia and cancer

Christensen

Luna³

et al. 2017

Cancer Cytopathology

View full text Add to dashboard Cite

Although both the Cobas and Aptima platforms offer highly sensitive tests for high-grade cervical lesions, Aptima HPV testing demonstrated significantly higher specificity and positive predictive value than Cobas testing for biopsy-confirmed ≥HSIL. The considerable difference may be related to the significant increase in E6/E7 expression after HPV DNA integration. The significantly higher specificity and overall accuracy of Aptima testing for ≥HSIL, resulting in the identification of high-risk populations that require immediate treatment and close follow-up, may prove useful in clinical risk stratification. Cancer Cytopathol 2017;125:652-7. © 2017 American Cancer Society.

show abstract

“…A number of studies and a meta‐analysis report higher specificity of the Aptima HPV assay and comparable sensitivity to the HPV DNA detection assay HC2 for the detection of CIN2+ in both colposcopy referral and primary screening settings …”

Section: Introductionmentioning

confidence: 99%

Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities

Tewari

White

Kelly

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background The aim of this study was to evaluate the clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay for the detection of CIN2+ disease in women referred to colposcopy with minor cytological abnormalities. Methods ThinPrep liquid‐based cytology samples were collected from 562 women referred to colposcopy with minor cytological abnormalities. HPV testing by both assays was performed on these samples. Clinical performances for detection of histologically diagnosed CIN2+ and CIN3+ were calculated. Results HPV prevalence by the Cobas 4800 HPV test was 58.2% and 53.0% women tested positive with the Aptima HPV assay in the entire study population. The Aptima HPV assay and the Cobas 4800 HPV test displayed equivalent sensitivity of 90.2% (95%CI, 83.4‐94.9) for the detection of CIN2+ disease. However, the Aptima HPV assay displayed greater specificity of 61.0% (95% CI, 54.0‐68.0) when compared to the Cobas 4800 HPV test 53.0% (95% CI, 46.0‐60.0), and this was significantly higher (P = .0004). The Aptima HPV assay also displayed higher specificity 76.5% (95% CI, 66.0‐85.0) in the ASCUS category in comparison to the Cobas 4800 HPV test 65.0% (95% 54.0‐75.0) which was statistically significant (P = .004). Conclusions Both the tests displayed similar sensitivity. However, the Aptima HPV assay was significantly more specific in the identification of women with CIN2+ disease in a colposcopy referral population.

show abstract

Performance of mRNA‐ and DNA‐based high‐risk human papillomavirus assays in detection of high‐grade cervical lesions

Cited by 11 publications

References 32 publications

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Immediate histopathologic follow‐up of cervista and aptima high‐risk HPV assays in women with LSIL cytology

Performance of Aptima and Cobas HPV testing platforms in detecting high‐grade cervical dysplasia and cancer

Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities

Contact Info

Product

Resources

About